By Doug Macron

Having taken the helm of Silence Therapeutics after the departure of its second chief executive in less than a year, the company's newly appointed CEO Tony Sedgwick sees continued advancement of the phase I cancer drug Atu027 as one of his key goals.

Meantime, Silence remains focused on demonstrating the potential of two new delivery technologies and expects to have a second clinical candidate incorporating one of them ready for human testing by early next year, Sedgwick said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.